Skip to content


  • Research article
  • Open Access
  • Open Peer Review

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

  • 1, 2,
  • 1, 2,
  • 1, 2,
  • 1, 2,
  • 1, 2 and
  • 1, 2Email author
BMC Cancer201313:363

  • Received: 6 December 2012
  • Accepted: 22 July 2013
  • Published:
Open Peer Review reports



Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our objective is to investigate the anticancer efficacy and mechanism of combined sorafenib and 5-FU therapy in vitro in HCC cell lines MHCC97H and SMMC-7721.


Drug effects on cell proliferation were evaluated by cell viability assays. Combined-effects analyses were conducted according to the median-effect principle. Cell cycle distribution was measured by flow cytometry. Expression levels of proteins related to the RAF/MEK/ERK and STAT3 pathways and to cell cycle progression (cyclin D1) were determined by western blot analysis.


Sorafenib and 5-FU alone or in combination showed significant efficacy in inhibiting cell proliferation in both cell lines tested. However, a schedule-dependent combined effect, associated with the order of compound treatments, was observed. Efficacy was synergistic with 5-FU pretreatment followed by sorafenib, but it was antagonistic with the reverse treatment order. Sorafenib pretreatment resulted in a significant increase in the half inhibitory concentration (IC50) of 5-FU in both cell lines. Sorafenib induced G1-phase arrest and significantly decreased the proportion of cells in S phase when administrated alone or followed by 5-FU. The RAF/MEK/ERK and STAT3 pathways were blocked and cyclin D1 expression was down regulated significantly in both cell lines by sorafenib; whereas, the kinase pathways were hardly affected by 5-FU, and cyclin D1 expression was up regulated.


Antitumor activity of sorafenib and 5-FU, alone or in combination, is seen in HCC cell lines. The nature of the combined effects, however, depends on the particular cell line and treatment order of the two compounds. Sorafenib appears to reduce sensitivity to 5-FU through down regulation of cyclin D1 expression by inhibiting RAF/MEK/ERK and STAT3 signaling, resulting in G1-phase arrest and reduction of the S-phase cell subpopulation when 5-FU is administrated after sorafenib, in which situation, combination treatment of the two agents results in antagonism; on the other hand, when sorafenib is administrated afterward, it can continue to work since it is not cell cycle specific, as a result, combination treatment of the two agents shows an additive-to-synergistic effect.


  • Hepatocellular carcinoma
  • Sorafenib
  • 5-fluorouracil
  • Cell cycle arrest


Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and ranks as the third leading cause of cancer-related death, accounting for 748,300 new cases and 695,900 deaths worldwide per year. Half of these cases and deaths are estimated to occur in China [1]. However, only approximately 30%–40% of patients are diagnosed in an early stage (0 or A) according to the Barcelona Clinic Liver Cancer staging system [2], which defines patients who are suitable for potentially curative approaches, such as surgical therapies (resection and liver transplantation) and locoregional procedures (radiofrequency ablation). For patients who meet the criteria for the intermediate stage (multinodular HCC, relatively preserved liver function, absence of cancer-related symptoms, and no evidence of vascular invasion or extrahepatic spread), transcatheter arterial chemoembolization (TACE) has been established as the standard of care, and this treatment may achieve a partial response or complete necrosis [3]. For patients with advanced HCC, sorafenib is the first agent discovered to result in favorable overall survival [4]. Regional hepatic arterial infusion chemotherapy (HAIC) has also been used in patients with advanced HCC in cases in which TACE is not indicated or is ineffective [5, 6].

The technique of TACE, including which drug is administrated, the scheduled followed after the first TACE or the follow-up imaging modalities, varies worldwide with no clear consensus. Among the agents commonly used in TACE and HAIC to inhibit cancer cell growth, 5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug. It initiates apoptosis by targeting thymidylate synthase (TS) and direct incorporation of 5-FU metabolites into DNA and RNA. However, its efficacy in HCC is poor [7], and the compound is associated with acquired and intrinsic resistance.

Sorafenib (BAY 43-9006, Nexavar) is an oral multikinase inhibitor that inhibits the serine-threonine kinases C-Raf and B-Raf, the receptor tyrosine kinase activity of vascular endothelial growth factor receptors -1, -2, and -3, platelet-derived growth factor receptor β, the receptor for the macrophage-colony stimulating factor (FLT3), Ret, and c-Kit. These kinases are involved in cell proliferation and tumor angiogenesis [8, 9]. In addition, increasingly more studies have pointed out that signal transducer and activator of transcription 3 (STAT3) is a major kinase-independent target of sorafenib in HCC [10, 11].

Recently, a phase II clinical trial has suggested that the combination of sorafenib and 5-fluorouracil is feasible, and the side effects are manageable for patients carefully selected for liver function and performance status [12]. However, preclinical experimental data explaining interaction mechanisms are widely missing. One previous study in our institute found that resistance to 5-FU was significantly associated with basal p-ERK expression levels in HCC cell lines while sorafenib inhibited ERK phosphorylation in a dose-dependent manner [13]. Chances are combination of sorafenib and 5-FU would exert a synergetic effect with the hypothesis that sorafenib could reverse the resistance to 5-FU of HCC cells by inhibiting p-ERK expressions. However, it is known that 5-FU is an S-phase-specific agent, whereas sorafenib causes G1-phase arrest in tumor cells [14]. The latter implies that sorafenib treatment would decrease the proportion of cells in S phase. And in such situation, tumor cells might become less susceptible to the 5-FU action. Therefore, the effects of combined sorafenib and 5-FU co-administration are uncertain.

In the present study, we initiated an in vitro study in HCC cell lines MHCC 97H and SMMC-7721 to investigate the anticancer efficacy and molecular mechanisms of combined administration of sorafenib and 5-FU.


Drug preparations

Sorafenib (Nexavar), N-(3-trifluoromethyl-4-chlorophenyl)-N-(4-(2-methylcarbamoylyridin-4-yl)oxy-phenyl) urea, was purchased from BioVision, Inc. (Milpitas, CA, USA). The compound was dissolved in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA) and diluted with Dulbecco's modified Eagle's medium (DMEM) or RPMI 1640 to the desired concentration; a final DMSO concentration of 0.1% (v/v) was present in cell studies. As solvent control, 0.1% DMSO alone was added to cultures. 5-Fluorouracil injection was purchased from Shanghai Xudong Haipu Pharmaceutical Co, Ltd. (Shanghai, China) and was diluted directly with cell culture medium to the desired concentration.

Cell lines

Human HCC tumor cell lines MHCC97H and SMMC-7721 were obtained from the Liver Cancer Institute of Fudan University (Shanghai, China) and cultured in DMEM or RPMI 1640 containing 10% v/v fetal bovine serum at 37°C in a humidified incubator containing 5% CO2. Unless otherwise indicated, cell culture reagents were purchased from GIBCO BRL (Grand Island, NE, USA).

Cell viability assay

Cells were plated in 96-well microtiter plates (4,000 per well) in 100 μL of serum-containing medium and incubated overnight at 37°C in the culture incubator. On the following day, the medium was replaced with fresh medium containing sorafenib, 5-FU, or a combination of the two agents at various concentrations. Treatment with sorafenib was done for 24 h at concentrations of 0, 0.25, 0.5, 1, 4, 8, 16, 32, 64, or 128 μM; that with 5-FU was for 48 h at concentrations of 0, 0.1, 1, 2, 4, 8, 16, 32, 64, 128, or 256 mg/L. Cell viability was measured using the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. The half maximal inhibitory concentration (IC50) values were calculated by nonlinear regression analysis using GraphPad Prism version 5.0 software (GraphPad Software, Inc., San Diego, CA, USA).

Combination index (CI) values were calculated using the median effect analysis method. A synergistic effect is defined as CI < 1, an additive effect as CI = 1, and an antagonistic effect as CI > 1.

Each condition was tested six times, and the results were confirmed in at least three independent experiments.

To further investigate combined effects of sorafenib and 5-FU on cell proliferation, growth inhibition, cell cycle distribution and pathways activities, six treatment groups were designed as follows: group control (0.1% DMSO); group S (treatment with 8 μM sorafenib for 24 h); group F (treatment with 4 mg/L 5-FU for 48 h); group (S + F) (concurrent treatment with 8 μM sorafenib and 4 mg/L 5-FU for 48 h); group S + F (8 μM sorafenib pretreatment for 24 h followed by 4 mg/L 5-FU treatment for another 48 h); group F + S (4 mg/L 5-FU treatment followed by 8 μM sorafenib for another 24 h).

Cell cycle assays

Exponentially growing cells were starved in serum-free medium for 24 h, after which they were grown in medium containing 10% serum with the compounds 8 μM sorafenib for 24 h or 4 mg/L 5-FU for 48 h, either alone or in combination patterns. Cell cycle analyses and quantification of genomic DNA fragmentation were performed using the Cell Cycle Detection Kit (KeyGEN, Nanjing, China) according to the manufacturer’s protocol. Cell cycle distributions were analyzed by flow cytometry with a Becton Dickinson FACS Calibur.

Western blot analysis

To prepare whole-cell protein extracts, cells were washed twice with phosphate-buffered saline and then lysed with a modified radio-immunoprecipitation assay buffer (50 mM Tris–HCl pH 7.4, 1% v/v NP-40, 0.25% v/v sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mg/mL of protease inhibitors (leupeptin and pepstatin), 1 mM Na3VO4, and 1 mM NaF) on ice for 30 min. Insoluble material was removed by centrifugation at 12,000 p/min for 15 min at 4°C. The protein concentration of cell lysates was measured using the Bradford Protein Assay Kit (Beyotime, Shanghai, China), and 30 μg of protein samples were loaded on 10% polyacrylamide gels containing sodium dodecyl sulfate and separated by electrophoresis at a constant voltage of 70 V for 2 h and transferred onto 0.45-μm polyvinylidene fluoride membranes (Millipore Corporation, Billerica, MA, USA) at a constant voltage of 100 V for 3 h at 0°C. The membranes were probed with the specific primary antibodies followed by a horseradish peroxidase-conjugate secondary antibody (1:5,000) and detected by enhanced chemiluminescence (ECL kit from Pierce, Rockford, IL, USA). The following primary antibodies were used: anti-C-RAF (1:1,000), anti-phospho-C-RAF (1:1,000), anti-ERK1/2 (1:1,000), and anti-phospho-ERK1/2 (Thr202/Tyr204) (1:1,000) from Cell Signaling Technology, Inc. (Danvers, MA, USA); anti-STAT-3 (1:1,000) and anti-phospho-STAT-3 (Tyr705) (1:1,000) from Abcam (Cambridge, MA, USA); and anti-cyclin D1 (1:1000) and anti-β-actin from Beyotime. Unless otherwise indicated, immunoblot reagents were purchased from Beyotime.

Statistical analysis

Statistical analysis was performed with SPSS 17.0 software (SPSS, Chicago, IL, USA). Measured values are expressed as mean ± standard deviation. Analysis of variance and least significant difference were used to evaluate statistical significance of differences between groups, and a P value of <0.05 was considered statistically significant.


Antitumor effects of sorafenib and 5-FU in HCC cell lines

Sorafenib and 5-FU both inhibited cell proliferation of the two HCC cell lines in a dose-dependent manner. The IC50 values of sorafenib were 17.82 ± 2.04 μM and 15.52 ± 0.95 μM in MHCC97H and SMMC-7721 cells, respectively, and the corresponding IC50 values of 5-FU were 116.59 ± 62.04 mg/L and 47.19 ± 13.02 mg/L, respectively. The dose–response curves for the two HCC cell lines are shown in Figure 1(A).
Figure 1
Figure 1

Antitumor effects of sorafenib and 5-fluorouracil (5-FU), alone or in combination, in hepatocellular carcinoma (HCC) cell lines. (A) Dose–response curves, correlating drug dose and cell viability, depict the effects of sorafenib and 5-FU on different HCC cell lines. The cell survival fraction is expressed relative to the untreated cells, set at 100. (B) Antiproliferation effects of 5-FU (4 mg/L, 48 h) and sorafenib (8 μM, 24 h), alone or in combination in different treatment sequences, in HCC cell lines. The cell numbers are represented as optical density (OD) values. (C) Inhibition rates of 5-FU (4 mg/L, 48 h) or sorafenib (8 μM, 24 h), alone or in combination in different treatment sequences, in HCC cell lines. The cell inhibition fraction is expressed relative to the untreated cells, set at 100. In this figure, values represent the mean ± standard deviation (SD), and each is the average of three independent determinations, with six replicates per experiment. S, sorafenib; F, 5-FU.

To evaluate the combined effects of sorafenib and 5-FU on cell proliferation and growth inhibition, six treatment groups were designed as in section “Methods”. The cell proliferation conditions of the six groups are shown in Figure 1(B), and inhibition rates of the six groups are listed in Figure 1(C) and Table 1. Our results generally suggest that inhibitory effects were equipotent to 5-FU monotherapy when 5-FU was concurrently administrated with sorafenib, better in the 5-FU-pretreated sequence, and, conversely, worse in the sorafenib pretreatment schedule (P values are shown in Table 1). That is, sequential treatment using 5-FU followed by sorafenib seems to be the optimal schedule for combined administration of the two agents.
Table 1

Inhibition rates (% of control) of sorafenib and 5-fluorouracil (5-FU), alone or in combination, in hepatocellular carcinoma (HCC) cells

Cell line



(S + F)/ p-value(vs. F)

S + F/ p-value(vs. F)

F + S/ p-value(vs. F)


18.63 ± 3.82

33.30 ± 5.67

29.87 ± 8.83/p = 0.328

22.98 ± 5.93/p = 0.023

42.57 ± 3.29/p = 0.017


20.60 ± 3.83

29.65 ± 4.74

30.35 ± 4.86/p = 0.781

23.23 ± 4.43/p = 0.016

53.50 ± 1.97/p = 0.000

S: sorafenib, F: 5-FU.

To further explore whether the combination of sorafenib with 5-FU results in synergism, additivity, or antagonism of inhibition of cell proliferation, combination index (CI) values were calculated using the median effect analysis method [15]. Sorafenib and 5-FU were administrated at certain concentration ratios in different sequences. The CI values are summarized in Table 2. Our data indicate that combination treatment of sorafenib and 5-FU largely resulted in antagonism in MHCC97H cells regardless of treatment order, with a degressive trend as drug concentrations increase. Further analysis indicated that the CI values of the 5-FU-pretreated group were smaller than those of the sorafenib-pretreated group and drew near 1 as drug concentrations increased, which indicated an additive-to-synergistic effect. Situations in SMMC-7721 cells were similar except that pretreatment with 5-FU showed an apparent synergistic effect.
Table 2

Combination index (CI) values of sorafenib and 5-fluorouracil (5-FU) combination in different treatment sequences in hepatocellular carcinoma (HCC) cells

Sorafenib concentration (μM)

5-FU concentration (mg/L)




(S + F)

S + F

F + S

(S + F)

S + F

F + S



4.33 ± 1.73

32.84 ± 4.26

3.88 ± 1.73

112.45 ± 28.23

67.40 ± 15.67

13.63 ± 9.81



2.07 ± 0.44

9.70 ± 3.96

5.20 ± 2.17

1.95 ± 1.01

13.50 ± 9.43

0.50 ± 0.34



1.47 ± 0.25

3.69 ± 2.08

3.25 ± 2.57

1.33 ± 0.38

1.80 ± 0.11

0.41 ± 0.20



1.18 ± 0.28

2.33 ± 1.24

1.13 ± 0.27

1.45 ± 0.33

1.66 ± 0.17

0.38 ± 0.05



0.99 ± 0.40

1.26 ± 0.30

0.75 ± 0.15

1.02 ± 0.09

1.71 ± 0.06

0.40 ± 0.04

CI Combination index. CI < 1 indicate synergy between the drugs; CI = 1 indicates additivity; and CI > 1 indicates antagonism. Values are expressed as the mean ± SD of at least three independent experiments performed in triplicate. S: sorafenib, F: 5-FU.

Sensitivity of HCC cells to 5-FU in combination with sorafenib

The sensitivity of HCC cell lines to 5-FU was determined by calculating the IC50 values from results of cell viability assays. In these experiments, four treatment groups were tested: group F (single treatment with 5-FU); group (S + F) (concurrent treatment with 5-FU and 8 μM sorafenib); group S + F (8 μM sorafenib pretreament for 24 h followed by 5-FU treatment); and group F + S (5-FU pretreatment followed by 8 μM sorafenib for another 24 h). Dose–response curves are shown in Figure 2, and IC50 values for 5-FU treatment of the four groups are listed in Table 3. Sensitivity to 5-FU varied greatly, depending on compound treatment order: sorafenib dramatically decreased the sensitivity to 5-FU when it was administrated prior to 5-FU, with the IC50 values increasing significantly (P < 0.001 for both) in both MHCC97H and SMMC-7721 cells. Conversely, the IC50 values of 5-FU decreased in both cell lines when sorafenib was administrated afterward.
Figure 2
Figure 2

Sensitivity of hepatocellular carcinoma (HCC) cells to 5-fluorouracil (5-FU) when treated in combination with sorafenib in vitro. Dose–response curves of 5-FU alone and combined with sorafenib, in different treatment sequences, are shown. HCC cell lines MHCC97H (A) and SMCC-7721 (B) were exposed to escalating doses of 5-FU, alone or combined with 8 μM sorafenib, in different treatment sequences. The cell survival fraction is expressed relative to the untreated cells, set at 100, and is expressed as the mean ± SD. Each value represents the average of three independent determinations with six replicates per experiment. Bars indicate standard error. S, sorafeinb; F, 5-FU.

Table 3

Sensitivity of hepatocellular carcinoma (HCC) cells to 5-fluorouracil (5-FU) (IC 50 of 5-FU (mg/L)) in different treatment strategies

Cell line


(S + F)/ p-value (vs. F)

S + F/ p-value (vs. F)

F + S/ p-value (vs. F)


116.59 ± 62.04

271.63 ± 57.08/p = 0.002

477.46 ± 146.45/p = 0.000

25.45 ± 9.72/p = 0.042


47.19 ± 13.02

43.16 ± 8.76/p = 0.948

1371.26 ± 237.70/p = 0.000

9.47 ± 1.03/p = 0.568

S: sorafenib, F: 5-FU.

Effects of sorafenib and 5-FU on cell cycle progress in HCC cell lines

Six treatment groups (group control, S, F, (S + F), S + F, and F + S, as described above) were tested. Cell cycle distributions are shown in Figure 3 and Tables 4 and 5. Our data indicate that sorafenib induced a G1-cell cycle arrest and significantly decreased the proportion of cells in S phase in both HCC cell lines when it was administrated alone or followed by 5-FU: proportions of cells in G1 phase increased from 47.53 ± 0.06% to 63.03 ± 0.95% and 66.70 ± 0.30% (P < 0.001 for both) in the two groups respectively and proportions of cells in S phase decreased from 40.97 ± 0.15% to 17.43 ± 0.85% and 12.27 ± 0.45% (P < 0.001 for both) in MHCC97H cells. For SMMC-7721 cells, proportions of cells in G1 phase increased from 63.83 ± 1.94% to 70.07 ± 0.70% and 81.83 ± 0.35% respectively (P < 0.001 for both) and proportions of cells in S phase decreased from 27.17 ± 2.41% to 8.45 ± 1.03% and 9.23 ± 0.12% respectively (P < 0.001 for both). Simultaneous treatment or pretreatment with 5-FU reversed this effect to some extent.
Figure 3
Figure 3

Effects of sorafenib and 5-fluorouracil (5-FU) on cell cycle progression in the hepatocellular carcinoma (HCC) cell lines MHCC97H (A) and SMMC-7721 (B). After serum starvation for 24 h, cells were exposed to sorafenib (8 μM, 24 h), 5-FU (4 mg/L, 48 h), or combination treatments of the two agents. The cell cycle distributions were then analyzed by flow cytometry. C, control; S, sorafeinb; F, 5-FU.

Table 4

Cell cycle distribution of MHCC97H cells after different drug treatments


G1 phase (%)/ p-value (vs. control)

S phase (%)/ p-value (vs. control)

G2/M phase (%)/ p-value (vs. control)


47.53 ± 0.06

40.97 ± 0.15

11.50 ± 0.20


63.03 ± 0.95/p = 0.000

17.43 ± 0.85/p = 0.000

19.50 ± 0.10/p = 0.000


62.60 ± 0.70/p = 0.000

25.23 ± 0.72/p = 0.000

12.17 ± 1.95/p = 0.367

(S + F)

60.50 ± 0.50/p = 0.000

22.00 ± 0.10/p = 0.000

17.47 ± 0.35/p = 0.000

S + F

66.70 ± 0.30/p = 0.000

12.27 ± 0.45/p = 0.000

21.03 ± 0.75/p = 0.000

F + S

64.30 ± 1.10/p = 0.000

32.80 ± 1.00/p = 0.000

2.91 ± 0.07/p = 0.000

S: sorafenib, F: 5-FU.

Table 5

Cell cycle distribution of SMMC-7721 cells after different drug treatments


G1 phase (%)/ p-value (vs control)

S phase (%)/ p-value (vs control)

G2/M phase (%)/ p-value (vs control)


63.83 ± 1.94

27.17 ± 2.41

9.00 ± 2.26


70.07 ± 0.70/p = 0.000

8.45 ± 1.03/p = 0.000

21.51 ± 1.63/p = 0.000


72.23 ± 0.35/p = 0.000

25.50 ± 0.80/p = 0.188

2.27 ± 1.15/p = 0.000

(S + F)

64.73 ± 0.15/p = 0.458

29.90 ± 0.10/p = 0.041

5.37 ± 0.27/p = 0.004

S + F

81.83 ± 0.35/p = 0.000

9.23 ± 0.12/p = 0.000

8.92 ± 0.44/p = 0.939

F + S

71.22 ± 2.80/p = 0.000

27.20 ± 2.30/p = 0.978

1.08 ± 0.40/p = 0.000

S: sorafenib, F: 5-FU.

Activation of RAF/MEK/ERK and STAT3 pathways and expression of cyclin D1

To identify the molecule mechanism of interactions between sorafenib and 5-FU, expression levels of proteins related to RAF/MEK/ERK and STAT3 pathways and to cell cycle progression (cyclin D1) were measured. Results showed that the levels of phosphorylated C-RAF, ERK, and STAT3 were significantly down regulated after sorafenib treatment in both cell lines (P < 0.001). Similar results were observed when sorafenib was concurrently administrated with 5-FU. Sequential therapies as well showed down-regulatory effects on expression of these proteins, although the differences were less than seen with sorafenib monotherapy. These pathways remained unchanged after exposure to 5-FU monotherapy. Moreover, sorafenib significantly down regulated cyclin D1 expression (P < 0.001), while 5-FU played an opposite role in both cell lines. Combined treatments also induced cyclin D1 down regulation, although the differences were less significant (Figure 4, Tables 6 and 7).
Figure 4
Figure 4

Activation of RAF/MEK/ERK and STAT3 pathways and expression levels of cyclin D1 after treatment with sorafenib and 5-fluorouracil (5-FU). Cells were treated with sorafenib (8 μM, 24 h), 5-FU (4 mg/L, 48 h), or combination of the two agents in different treatment sequences. Western blot analysis was performed to detect the expression levels of p-C-RAF, total C-RAF, p-ERK1/2, total ERK1/2, p-STAT3 (Y705), total STAT3, and cyclin D1. Loading controls were carried out by probing the blots for β-actin. Representative western blots (A) and quantification analysis (B and C) are shown. Asterisks (*) indicate significant differences in protein expression (P < 0.05). C, control; S, sorafeinb; F, 5-FU.

Table 6

Relative expression levels of proteins in MHCC97H cells after different drug treatments



S/ p-value (vs. control)

F/ p-value (vs. control)

(S + F)/ p-value (vs. control)

S + F/ p-value (vs. control)

F + S/ p-value (vs. control)



0.47 ± 0.10/p = 0.000

0.95 ± 0.06/p = 0.544

0.43 ± 0.07/p = 0.000

0.68 ± 0.12/p = 0.003

0.61 ± 0.18/p = 0.001



0.95 ± 0.06/p = 0.336

0.97 ± 0.09/p = 0.631

0.98 ± 0.08/p = 0.703

0.95 ± 0.07/p = 0.386

1.02 ± 0.07/p = 0.737



0.47 ± 0.05/p = 0.000

0.96 ± 0.04/p = 0.200

0.45 ± 0.05/p = 0.000

0.64 ± 0.04/p = 0.000

0.54 ± 0.01/p = 0.000



0.92 ± 0.06/p = 0.099

0.95 ± 0.05/p = 0.255

1.00 ± 0.07/p = 0.965

0.93 ± 0.05/p = 0.133

0.98 ± 0.06/p = 0.611



0.38 ± 0.05/p = 0.000

0.96 ± 0.03/p = 0.193

0.38 ± 0.02/p = 0.000

0.43 ± 0.06/p = 0.000

0.40 ± 0.05/p = 0.000



0.97 ± 0.21/p = 0.734

0.92 ± 0.05/p = 0.416

0.93 ± 0.05/p = 0.417

0.95 ± 0.12/p = 0.612

0.97 ± 0.08/p = 0.720

Cyclin D1


0.56 ± 0.05/p = 0.002

1.55 ± 0.29/p = 0.000

0.64 ± 0.12/p = 0.008

0.70 ± 0.09/p = 0.023

0.61 ± 0.07/p = 0.004

C: control, S: sorafenib, F: 5-FU.

Table 7

Relative expression levels of proteins in SMMC-7721 cells after different drug treatments



S/ p-value (vs. control)

F/ p-value (vs. control)

(S + F)/ p-value (vs. control)

S + F/ p-value (vs. control)

F + S/ p-value (vs. control)



0.47 ± 0.12/p = 0.000

0.93 ± 0.06/p = 0.185

0.40 ± 0.07/p = 0.000

0.64 ± 0.04/p = 0.000

0.61 ± 0.05/p = 0.000



0.90 ± 0.08/p = 0.154

1.07 ± 0.12/p = 0.302

0.95 ± 0.06/p = 0.431

1.05 ± 0.10/p = 0.459

1.06 ± 0.08/p = 0.408



0.54 ± 0.03/p = 0.000

1.06 ± 0.12/p = 0.403

0.66 ± 0.09/p = 0.000

0.77 ± 0.03/p = 0.005

0.63 ± 0.05/p = 0.000



1.00 ± 0.06/p = 0.971

1.08 ± 0.09/p = 0.193

0.94 ± 0.07/p = 0.307

1.09 ± 0.07/p = 0.141

1.00 ± 0.08/p = 0.996



0.51 ± 0.02/p = 0.000

0.95 ± 0.06/p = 0.180

0.63 ± 0.06/p = 0.000

0.82 ± 0.03/p = 0.000

0.78 ± 0.06/p = 0.000



1.03 ± 0.03/p = 0.627

1.06 ± 0.07/p = 0.376

1.03 ± 0.13/p = 0.621

1.08 ± 0.12/p = 0.235

1.10 ± 0.05/p = 0.135

Cyclin D1


0.53 ± 0.08/p = 0.000

1.83 ± 0.18/p = 0.000

0.57 ± 0.04/p = 0.000

0.89 ± 0.07/p = 0.174

0.76 ± 0.05/p = 0.008

C: control, S: sorafenib; F: 5-FU.


Though few basic scientific studies have provided substantial evidence about the activity of 5-FU in combination with sorafenib in HCC, combined effects of the two agents on other solid tumors are controversial. Thomas and colleagues [16] have shown that single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer, and combination therapy shows no additional effect. On the other hand, a recent study demonstrates that combination therapy of 5-FU and sorafenib exerts a synergistic antitumor effect in renal cell carcinoma [17]. As sorafenib and 5-FU are both commonly used in HCC patients, it is meaningful and instructive to investigate the combined effects in HCC cells.

We find that both sorafenib and 5-FU display antitumor effects in the HCC cell lines MHCC97H and SMMC-7721. Combined effects of the two agents are schedule-dependent: concurrent treatment shows similar efficacy, while pretreatment with sorafenib exacerbates inhibitory effects, but 5-FU pretreatment followed by sorafenib ameliorates inhibitory effects compared with 5-FU monotherapy. According to variations in IC50 values, we find that HCC cells become less sensitive to 5-FU after pretreatment with sorafenib, yet more sensitive when 5-FU pretreatment is followed by sorafenib. That is to say, sequential treatment of 5-FU followed by sorafenib seems to be the optimal schedule for combined administration of the two agents.

Manov and colleagues [18] found that sorafenib, when combined with doxorubicin, increased survival and reduced doxorubicin-induced autophagy by inhibiting MEK/ERK and inducing degradation of cyclin D1 in the HCC cell line Hep3B. Based on these results, they believe that the use of MEK/ERK inhibitors in combination with chemotherapeutics might have possible antagonistic effects. Our results tend to lead to a similar conclusion. Thus, we have tried to understand the mechanism by examining some of the sorafenib-related pathways, like the STAT3 and RAF/MEK/EKR cascade. In addition, we have analyzed cell cycle distribution and expression of proteins associated with cell cycle progression, as it is known that 5-FU is an S-phase-specific chemotherapeutic drug.

Our data reveal that sorafenib efficiently blocks STAT3 and RAF/MEK/EKR pathways, showing down regulation of p-C-RAF, p-ERK, and p-STAT3, while 5-FU shows almost no effect. No changes were observed for total C-RAF, ERK and STAT3 proteins by any of the treatments. Furthermore, sorafenib slows cell cycle progression by inducing a G1-phase arrest, which results in a reduction of the S-phase subpopulation. Sorafenib significantly down regulates cyclin D1 expression in HCC cells, while 5-FU has an opposite effect. Since expression levels of cyclin D1 in combination groups were as well down-regulated, we believe that sorafenib plays a dominant role in regulating cell cycle distributions and cyclin D1 expressions in combined treatments of sorafenib and 5-FU.

Signaling through RAF/MEK/ERK plays a crucial role in cell proliferation, differentiation, malignant transformation, and apoptosis [19, 20]. It has been thoroughly demonstrated that sorafenib exhibits remarkable antitumor activity in HCC in vitro and in vivo, through targeting the RAF/MEK/EKR cascade [21, 22]. Our results agree well with these reports.

The STAT3 proteins have dual roles as cytoplasmic signaling proteins and nuclear transcription factors that activate a diverse set of genes, including some that are importantly implicated in tumor cell proliferation, survival, invasion, cell-cycle progression, tumor angiogenesis, and tumor cell evasion of the immune system [2325]. Recently, sorafenib has been shown to suppress tumor growth by decreasing STAT3 phosphorylation in a group of human malignancies [2629], including HCC [11, 30]. As the results we obtained from tests of STAT3 activation after sorafenib treatment are in line with previous studies, we have gained further insight into the mechanism of anti-cancer effects of sorafenib.

It is well known that key genes in cell-cycle control, such as cyclin D1, an important regulator of G1-to-S phase progression [31], are regulated by STAT3 [25, 26]. In addition, some studies have demonstrated that cyclin D1 is regulated by both the RAF/ MEK/ ERK and phosphoinositide-3 kinase (PI3K)/Akt pathways [32, 33]. Interestingly, some recent studies point out that sorafenib inhibits growth and metastasis of HCC in part by blocking the MEK/ERK/STAT3 and PI3K/Akt/STAT3 signaling pathways [11]; and that sorafenib-induced Tyr705 STAT3 dephosphorylation is mediated by Raf inhibition, as the Raf-inhibitor ZM336372 also results in Tyr705 STAT3 dephosphorylation [34]. Therefore, we have reasons to believe that STAT3 somehow functions downstream of RAF/MEK/ERK signaling.

A recent study has indicated that 5-FU resistance in oral squamous cell carcinoma (OSCC) cell lines HSC-3 and CA9-22, both of which are hypoxia-sensitive (HS), is due to suppressed growth rate and G1-phase accumulation [35]. Similarly, we find that sorafenib causes a G1-phase arrest of HCC cells and, as well, decreases sensitivity to 5-FU, leading to an antagonistic effect of the two agents in the sorafenib-pretreatment strategy.

To summarize, combination effects of sorafenib and 5-FU vary between the different treatment orders. On the whole, antitumor effects are highest in 5-FU pretreatment strategies, and they are lowest following sorafenib pretreatment patterns. Since 5-FU is an S-phase-specific chemotherapeutic drug, it works less efficiently after exposure to sorafenib because of reduction in the proportion of S-phase cells. In contrast, sorafenib exerts further antitumor effects after 5-FU treatments, as the mechanism of sorafenib is cell cycle-independent.

Our in vitro study is limited to the cellular level, and in vivo studies are needed that cover sequential therapy of cell cycle-dependent chemotherapeutic drugs and molecular-targeted drugs. Still, our results do provide some important clues that may help guide drug selection and therapeutic strategy used in clinical treatments.


From our experimental results and what is known in the literature, we conclude that (1) sorafenib and 5-FU both possess antitumor activity in HCC cells; (2) compared with 5-FU monotherapy, combination treatment with sorafenib and 5-FU shows weaker effects when sorafenib is followed by 5-FU, while the effect is stronger when 5-FU is followed by sorafenib; and (3) sorafenib pretreatment reduces the sensitivity of HCC cells to 5-FU by down regulating cyclin D1 expression via inhibition of RAF/MEK/ERK and STAT3 signaling, which in turn results in G1-phase arrest and S-phase reduction.



This research project was supported in part by grants from the Shanghai Health Bureau (No.2010114B-228).

Authors’ Affiliations

Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, 200032, People’s Republic of China


  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. Ca-A Canc J Clinician. 2011, 61: 69-90. 10.3322/caac.20107.View ArticleGoogle Scholar
  2. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet. 2012, 379: 1245-1255. 10.1016/S0140-6736(11)61347-0.View ArticlePubMedGoogle Scholar
  3. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Canc Treat Rev. 2011, 37: 212-220. 10.1016/j.ctrv.2010.07.006.View ArticleGoogle Scholar
  4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. New England J Med. 2008, 359: 378-390. 10.1056/NEJMoa0708857.View ArticleGoogle Scholar
  5. Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K, et al: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol. 2012, 27: 1850-1857. 10.1111/j.1440-1746.2012.07276.x.View ArticlePubMedGoogle Scholar
  6. Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, et al: Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol. 2012, 18: 3426-3434. 10.3748/wjg.v18.i26.3426.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C: The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells A-8089-2010. J Canc Res Clin Oncol. 2005, 131: 385-394. 10.1007/s00432-004-0664-6.View ArticleGoogle Scholar
  8. Beeram M, Patnaik A, Rowinsky EK: Raf: A strategic target for therapeutic development against cancer. J Clin Oncol. 2005, 23: 6771-6790. 10.1200/JCO.2005.08.036.View ArticlePubMedGoogle Scholar
  9. Liu L, Cao YC, Chen C, Zhang XM, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Canc Res. 2006, 66: 11851-11858. 10.1158/0008-5472.CAN-06-1377.View ArticleGoogle Scholar
  10. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF: Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol. 2011, 55: 1041-1048. 10.1016/j.jhep.2011.01.047.View ArticlePubMedGoogle Scholar
  11. Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J: Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol. 2011, 17: 3922-3932. 10.3748/wjg.v17.i34.3922.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S: Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Canc Chemother Pharmacol. 2012, 69: 773-780. 10.1007/s00280-011-1753-2.View ArticleGoogle Scholar
  13. Zhang Z, Zhou XY, Shen HJ, Wang DX, Wang YH: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009, 7: 10.1186/1741-7015-7-41.Google Scholar
  14. Plastaras JP, Kim S, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, et al: Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Canc Res. 2007, 67: 9443-9454. 10.1158/0008-5472.CAN-07-1473.View ArticleGoogle Scholar
  15. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies B-4111-2009. Pharmacol Rev. 2006, 58: 621-681. 10.1124/pr.58.3.10.View ArticlePubMedGoogle Scholar
  16. Wehler TC, Hamdi S, Maderer A, Graf C, Gockel I, Schmidtmann I, Hainz M, Berger MR, Theobald M, Galle PR, et al: Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft-no benefit of combination therapy. Int J Colorectal Dis. 2012, 10.1007/s00384-012-1551-2.Google Scholar
  17. Miyake M, Anai S, Fujimoto K, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Tomioka A, Tanaka N, Hirao Y: 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett. 2012, 3: 1195-1202.PubMedPubMed CentralGoogle Scholar
  18. Manov I, Pollak Y, Broneshter R, Iancu TC: Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib - the role of extracellular signal-regulated kinase counteraction. FEBS J. 2011, 278: 3494-3507. 10.1111/j.1742-4658.2011.08271.x.View ArticlePubMedGoogle Scholar
  19. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007, 1773: 1263-1284. 10.1016/j.bbamcr.2006.10.001.View ArticlePubMedGoogle Scholar
  20. Cagnol S, Chambard JC: ERK and cell death: mechanisms of ERK-induced cell death–apoptosis, autophagy and senescence. FEBS J. 2010, 277: 2-21. 10.1111/j.1742-4658.2009.07366.x.View ArticlePubMedGoogle Scholar
  21. Wilhelm SM, Carter C, Tang LY, Wilkie D, McNabola A, Rong H, Chen C, Zhang XM, Vincent P, McHugh M, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Canc Res. 2004, 64: 7099-7109. 10.1158/0008-5472.CAN-04-1443.View ArticleGoogle Scholar
  22. Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen L, Yang PY, Gu K, Meng ZQ: Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Mol Biol Rep. 2012, 39: 1683-1689. 10.1007/s11033-011-0908-x.View ArticlePubMedGoogle Scholar
  23. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19: 2474-2488. 10.1038/sj.onc.1203527.View ArticlePubMedGoogle Scholar
  24. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Canc. 2009, 9: 798-809. 10.1038/nrc2734.View ArticleGoogle Scholar
  25. Yu H, Jove R: The STATs of cancer–new molecular targets come of age. Nat Rev Canc. 2004, 4: 97-105. 10.1038/nrc1275.View ArticleGoogle Scholar
  26. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, et al: Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Canc Ther. 2008, 7: 3519-3526. 10.1158/1535-7163.MCT-08-0138.View ArticleGoogle Scholar
  27. Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R: Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3. Mol Canc Ther. 2010, 9: 953-962. 10.1158/1535-7163.MCT-09-0947.View ArticleGoogle Scholar
  28. Huang SB, Sinicrope FA: Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells. Mol Canc Ther. 2010, 9: 742-750. 10.1158/1535-7163.MCT-09-1004.View ArticleGoogle Scholar
  29. Zhao W, Zhang T, Qu BQ, Wu XX, Zhu X, Meng FY, Gu YH, Shu YQ, Shen Y, Sun Y, Xu QA: Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anti-Canc Drugs. 2011, 22: 79-88. 10.1097/CAD.0b013e32833f44fd.View ArticleGoogle Scholar
  30. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ, Cheng AL: Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3. Clin Canc Res. 2010, 16: 5189-5199. 10.1158/1078-0432.CCR-09-3389.View ArticleGoogle Scholar
  31. Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Canc. 2007, 6: 24-View ArticleGoogle Scholar
  32. Huynh H, Do PT, Nguyen TH, Chow P, Tan PH, Quach TH, Van T, Soo KC, Tran E: Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int J Oncol. 2004, 25: 1839-1847.PubMedGoogle Scholar
  33. Stacey DW: Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003, 15: 158-163. 10.1016/S0955-0674(03)00008-5.View ArticlePubMedGoogle Scholar
  34. Blechacz B, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ: Sorafenib Inhibits Signal Transducer and Activator of Transcription-3 Signaling in Cholangiocarcinoma Cells by Activating the Phosphatase Shatterproof 2. Hepatology. 2009, 50: 1861-1870. 10.1002/hep.23214.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M, Shintani S: Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol. 2009, 45: 109-115. 10.1016/j.oraloncology.2008.04.002.View ArticlePubMedGoogle Scholar
  36. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:


© Deng et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.